UB 421

Drug Profile

UB 421

Alternative Names: dB4; mAb B4; UB-421

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator United Biomedical
  • Developer United Biomedical; United BioPharma
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 28 Nov 2016 United Biomedical plans a phase III trial for HIV-1 infections
  • 01 Jul 2016 United BioPharma completes a phase II trial in HIV-1 infections (Monotherapy) in Taiwan (NCT02369146)
  • 01 Jun 2015 Phase-II clinical trials in HIV-1 infections (Monotherapy) in Taiwan (IV) (NCT02369146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top